This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The company's earnings release, most recent annual report on Form 10-K, and other filings with the Securities and ExchangeCommission contain additional information concerning factors that could cause actual results to differ materially from those projected in forward-looking statements. We're seeing backlogs maintained.
Securities and ExchangeCommission, including the company's latest annual report on Form 10-K. Returning to our third quarter results, CMC's reported net earnings of 119.4 and a trailing EBITDA return on invested capital of 11.3%. million, or $1.02 per diluted shares, on net sales of 2.1
These risk factors are discussed in detail in our Form 10-K filed for the year ended December 31st, 2023 and in our definitive proxy statement filed with the Securities and ExchangeCommission on October 31st, 2024, as updated in our subsequent reports filed with the Securities and ExchangeCommission.
These risk factors are discussed in detail in our Form 10-K filed for the year ended December 31st, 2023, as updated in our subsequent reports filed with the Securities and ExchangeCommission. As we said in the past, we are focused and will continue to invest in this flywheel of demand and supply. million shares for $17.8
million, an increase of 29% from the prior quarter, producing an annualized return on invested capital of 19.1%. Each transaction supports CMC's strategy by either securing critical inputs to our manufacturing operations or enhancing our ability to serve our customers. million or $2.02 per diluted share. million and $2.54
I would now like to turn the conference over to Rana Schirmer, director of SEC reporting. Rana Schirmer -- Director of Securities and ExchangeCommission Reporting Thank you, operator. Good afternoon, everyone, and welcome to our fiscal 2023 fourth quarter investment -- investor conference call and webcast.
Securities and ExchangeCommission, including the company's latest annual report on Form 10-K. Equipment is now being installed, and we remain on track for the commissioning process to begin in late calendar 2025. and a trailing 12-month return on invested capital of 10%. million or $0.90 compares to 14.7%
Securities and ExchangeCommission, the Brazilian Comissao Valores Mobiliarios. This helps dilute fixed costs, particularly as we have excess logistics capacity while capital intensity is very low, which implies a very healthy return on invested capital. On the capex, we've updated. The main one is S11D.
I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning, and the disclosures in our SEC filings which are all available on the IR website on pfizer.com. Foreign exchange movements had an immaterial impact compared to last year's fourth quarter. Operator, please assemble the queue.
The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and ExchangeCommission. Your line is open.
Before we begin, I want to remind you that some of the comments we'll make today are forward-looking statements within the federal securities laws and address our expectations for the future performance or operating results of our company. These reports, when filed, are available on the UPS investor relations website and from the SEC.
These risk factors are discussed in detail in our Form 10-K filed for the year ended December 31st, 2023, and our definitive proxy statement filed with the Securities and ExchangeCommission on October 31st, 2024, and as updated in our subsequent reports filed with the Securities and ExchangeCommission.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content